DDInter571 DDInter1747
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Diphenoxylate {u} (Compound) resembles {v} (Compound) Methadone
Diphenoxylate {u} (Compound) resembles {v} (Compound) Sulfinpyrazone
Diphenoxylate {u} (Compound) binds {v} (Gene) OPRM1
Diphenoxylate {u} (Compound) downregulates {v} (Gene) HIST1H2BK
Diphenoxylate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketamine
Diphenoxylate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Droperidol
Diphenoxylate {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levacetylmethadol
Diphenoxylate (Compound) resembles Methadone (Compound)
Diphenoxylate (Compound) resembles Sulfinpyrazone (Compound)
Diphenoxylate (Compound) binds OPRM1 (Gene)
Diphenoxylate (Compound) downregulates HIST1H2BK (Gene)
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Ketamine
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Droperidol
Diphenoxylate (Compound) resembles Levacetylmethadol (Compound) and Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol